PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26124N0588Takhzyro (lanadelumab-flyo) 150mg ML INJ syringe — Takeda Pharmaceuticals America, Inc

Takeda Pharmaceuticals America, Inc holds $6.5M across 96 federal awards, concentrated at Department of Justice (DOJ). This PIID sits alongside 4 related awards under parent V797D50492. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended May 15, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

261-Network Contract Office 21 (36C261)

Awarding office

Takeda Pharmaceuticals America, Inc

Recipient

May 15, 2024

PoP end

$216K

Obligated

$221K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Takeda Pharmaceuticals America, Inc — $90

Contract facts

Federal

Contract number36C26124N0588

Also listed as36C261-24-N-0588

Also listed asV797D50492-36C26124N0588

Agency261-Network Contract Office 21 (36C261)

Awarding office261-Network Contract Office 21 (36C261)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentTakeda Pharmaceuticals America, Inc

CAGE4DE70

UEIDDEVYUAXJ624

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVV797D50492

Place of performanceLEXINGTON MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startApr 15, 2024

PoP end (current)May 15, 2024

Obligated$216K

Current value$221K

Potential value$221K

TAKHZYRO (LANADELUMAB-FLYO) 150MG/ML INJ,SYRINGE,2ML, NDC: 47783-0646-01 is a federal award for 261-Network Contract Office 21 (36C261) held by Takeda Pharmaceuticals America, Inc. Estimated value $221K ($216K obligated). Current period of performance ends May 15, 2024. Last award drew 1 bidder. Place of performance: LEXINGTON MA.

TAKHZYRO (LANADELUMAB-FLYO) 150MG/ML INJ,SYRINGE,2ML, NDC: 47783-0646-01

Recompete timing

Public

● Past PoP end (828 days ago)

Current PoP ended May 15, 2024 (828 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Takeda Pharmaceuticals America, Inc — $6.5M obligated across 96 awards (firm-wide, all agencies) · lead buyer Department of Justice (DOJ).

% of firm-wide obligated ($6.5M) · all agencies

Department of Justice (DOJ)$4.0M · 62%Department of Veterans Affairs (VA)$2.5M · 38%Department of Defense (DOD)$20K · 0%

Open full company profile →

Related awards

Same parent · incumbent

15B50926F00000076

FY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER

$549K

Sep 30, 2026

15B50926F00000018

FY26 TAKEDA OCT-NOV

$320K

Sep 30, 2026

36C26026P0420

GAMMAGARD LIQUID ERC - GLOBULIN,IMMUNE (IV) 10% INJ

$108K

Sep 30, 2026

36C26026F0130

ADZYNMA 1500IU INJ,LYPHL.

$179K

Jan 3, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26124N0588?

36C26124N0588 (Takhzyro (lanadelumab-flyo) 150mg ML INJ syringe) is a 261-Network Contract Office 21 (36C261) award with a potential value of $221K, currently held by Takeda Pharmaceuticals America, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C261-24-N-0588?

36C261-24-N-0588 is the dashed form of PIID 36C26124N0588 (Takhzyro (lanadelumab-flyo) 150mg ML INJ syringe), held by Takeda Pharmaceuticals America, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26124N0588?

261-Network Contract Office 21 (36C261) awarded 36C26124N0588 to Takeda Pharmaceuticals America, Inc (potential $221K).

Who is the incumbent on 36C26124N0588?

Takeda Pharmaceuticals America, Inc is the incumbent with $6.5M across 96 related awards in SCOUT’s public footprint. The current period of performance ends May 15, 2024.

When does Takeda Pharmaceuticals America, Inc’s 36C26124N0588 come up for recompete?

SCOUT tracks a period-of-performance end of May 15, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jan 28, 2025